Drug reference

Olodaterol

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 288

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Maintenance treatment of chronic obstructive pulmonary Respiratory system disease ▶BY INHALATION ▶Adult: 5 micrograms once daily DOSE EQUIVALENCE AND CONVERSION ▶2 puffs is equivalent to 5 micrograms.

PDF page 288

Cautions

Aneurysm. convulsive disorders

PDF page 288

Safety

Important Safety Information

MHRA/CHM ADVICE: PRESSURISED METERED DOSE INHALERS (PMDI): RISK OF AIRWAY OBSTRUCTION FROM ASPIRATION OF LOOSE OBJECTS (JULY 2018) See Respiratory system, drug delivery p. 249.

PDF page 288

Interactions

→Appendix 1: beta2 agonists

PDF page 288

Side Effects

▶Uncommon Nasopharyngitis. rash ▶Rare or very rare Arthralgia. hypertension ▶Frequency not known Angina pectoris. dry mouth. fatigue. hypotension. insomnia. malaise. metabolic acidosis. muscle spasms. nervousness

PDF page 288

Pregnancy

Manufacturer advises avoid—no information available.

PDF page 288

Breast Feeding

Manufacturer advises avoid— present in milk in animal studies.

PDF page 288

Hepatic Impairment

Manufacturer advises caution in severe hepatic impairment (no information available).

PDF page 288

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Inhalation solution ▶Striverdi Respimat (Boehringer Ingelheim Ltd) A Olodaterol (as Olodaterol hydrochloride) 2.5 microgram per 1 dose Striverdi Respimat 2.5micrograms/dose inhalation solution cartridge with device | 60 dose P £26.35 DT = £26.35 Striverdi Respimat 2.5micrograms/dose inhalation solution refill cartridge | 60 dose P £26.35 DT = £26.35 Combinations available: Tiotropium with olodaterol, p. 263 eiiii F 264

PDF page 288

Clinical care

Patient And Carer Advice

Patients or carers should be given advice on how to administer olodaterol solution for inhalation.

PDF page 288

Dose text by age group

Adult

5 micrograms once daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 288

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Olodaterol

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 288

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

PDF page 288

Cautions

Aneurysm. convulsive disorders

PDF page 288

Safety

Important Safety Information

MHRA/CHM ADVICE: PRESSURISED METERED DOSE INHALERS (PMDI): RISK OF AIRWAY OBSTRUCTION FROM ASPIRATION OF LOOSE OBJECTS (JULY 2018) See Respiratory system, drug delivery p. 249.

PDF page 288

Interactions

→Appendix 1: beta2 agonists

PDF page 288

Side Effects

PDF page 288

Pregnancy

Manufacturer advises avoid—no information available.

PDF page 288

Breast Feeding

Manufacturer advises avoid— present in milk in animal studies.

PDF page 288

Hepatic Impairment

Manufacturer advises caution in severe hepatic impairment (no information available).

PDF page 288

Dose and formulations

Medicinal Forms

PDF page 288

Clinical care

Patient And Carer Advice

Patients or carers should be given advice on how to administer olodaterol solution for inhalation.

PDF page 288

Dose text by age group

Adult

5 micrograms once daily

First-line fragment. Read the complete Indications and Dose section above.

PDF page 288

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.